LBA7501 Background: While the benefit of EGFR tyrosine kinase inhibitors in the treatment
of patients with NSCLC harboring EGFR mutations has been widely established, their value …

7178 Background: Erlotinib demonstrated improved survival in previously treated NSCLC,
but did not affect survival in untreated NSCLC when used with concurrent chemotherapy. A …

9506 Background: In NEJ026, a phase III trial comparing bevacizumab plus erlotinib (BE) to
erlotinib monotherapy (E) for EGFR-mutated non-small-cell lung cancer (NSCLC), we …

7514 Background: EGFR mutant NSCLC is exquisitely sensitive to EGFR tyrosine kinase
inhibitors (TKIs). Retrospective data suggests adjuvant TKIs may improve outcomes. This …

8001 Background: Erlotinib (E), a small-molecule EGFR TKI, is proven to extend survival
versus placebo (P) in 2nd/3rd-line advanced NSCLC. The phase III SATURN study …

7028 Background: Erlotinib is a potent HER1/EGFR TKI that provides survival benefit as a
single agent in 2nd and/3rd line NSCLC. The combination trial TALENT failed to show …

8063 Background: Options are limited for pts with NSCLC following chemotherapy and E.
PF299 is an oral irreversible small molecule inhibitor of the HER-1,-2, and-4 tyrosine …

Erlotinib is approved for the treatment of patients with EGFR mutation positive, metastatic
NSCLC. It is also approved as second/third line therapy for EGFR mutation negative …

Background: Pemetrexed and erlotinib represent different agents commonly used for the
second-line treatment of patients with advanced-stage non-small cell lung cancer (NSCLC) …

7031 Background: Erlotinib and gefitinib produce dramatic responses in a subset of pts with
NSCLC. Mutations in the EGFR tyrosine kinase (TK), EGFR amplification or polysomy and …